康希諾生物(06185.HK)業績快報:2024年營收翻倍增長,疫苗商業化加速推進
格隆匯2月27日丨康希諾生物(06185.HK)發佈2024年度業績快報公告,報告期內,集團實現營業收入人民幣8.46億元,同比增加137.01%;實現歸屬於母公司所有者的淨虧損人民幣3.79億元,同比虧損減少74.45%;實現歸屬於母公司所有者的扣除非經常性損益的淨虧損人民幣4.41億元,同比虧損減少72.61%。報告期內,集團工作重點主要爲推進流腦結合疫苗的商業化進程及非新冠疫苗產品的研發。
疫苗商業化端,集團持續搭建銷售管道,ACYW135羣腦膜炎球菌多糖結合疫苗(CRM197載體)(“MCV4”,商品名稱:曼海欣®)作爲中國市場上唯一的四價流腦結合疫苗,市場佔有率不斷提升,同時集團經營受全球公共衛生事件的影響已經基本消除。因此,集團營業收入較去年同期快速增長,帶動了集團經營成果的提升。
疫苗研發端,集團持續推進在研管線進展,多款候選產品達成重要里程碑,向產業化、商業化快速邁進。集團優化資源配置,推進降本增效措施,資源使用效率持續提升。報告期內,管理費用、研發費用同比下降,銷售費用率也呈下降趨勢。集團在產銷協同方面不斷優化,資產減值損失較去年同期大幅減少。綜上,集團營業收入的大幅增長及經營效率的提升,使得本年度歸屬於母公司所有者的淨虧損同比大幅減少。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.